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Abstract
Purpose Combination therapy of male lower urinary tract
symptoms with a1-adrenoceptor and muscarinic receptor
antagonists attracts increasing interest. Propiverine is a
muscarinic receptor antagonist possessing additional
properties, i.e., block of L-type Ca
2? channels. Here, we
have investigated whether propiverine and its metabolites
can additionally antagonize a1-adrenoceptors.
Methods Human prostate and porcine trigone muscle
strips were used to explore inhibition of a1-adrenoceptor-
mediated contractile responses. Chinese hamster ovary
(CHO) cells expressing cloned human a1-adrenoceptors
were used to determine direct interactions with the receptor
in radioligand binding and intracellular Ca
2? elevation
assays.
Results Propiverine concentration-dependently reversed
contraction of human prostate pre-contracted with 10 lM
phenylephrine (-log IC50 [M] 4.43 ± 0.08). Similar inhi-
bition was observed in porcine trigone (-log IC50
5.01 ± 0.05), and in additional experiments consisted
mainly of reduced maximum phenylephrine responses. At
concentrations C1 lM, the propiverine metabolite M-14
also relaxed phenylephrine pre-contracted trigone strips,
whereas metabolites M-5 and M-6 were ineffective. In
radioligand binding experiments, propiverine and M-14
exhibited similar afﬁnity for the three a1-adrenoceptor
subtypes with -log Ki [M] values ranging from 4.72 to
4.94, whereas the M-5 and M-6 did not affect [
3H]-prazosin
binding. In CHO cells, propiverine inhibited a1-adreno-
ceptor-mediated Ca
2? elevations with similar potency as
radioligand binding, again mainly by reducing maximum
responses.
Conclusions In contrast to other muscarinic receptor
antagonists, propiverine exerts additional L-type Ca
2?-
channel blocking and a1-adrenoceptor antagonist effects. It
remains to be determined clinically, how these additional
properties contribute to the clinical effects of propiverine,
particularly in male voiding dysfunction.
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Introduction
The medical treatment of male lower urinary tract symp-
toms (LUTS) typically consists primarily of a1-adreno-
ceptor antagonists, but in many patients this provides
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ceptor and muscarinic receptor antagonists may be more
effective, particularly against storage symptoms [1, 2].
While most combination studies have used tolterodine as
the muscarinic antagonist, several have also been based on
propiverine [1–4].
Propiverine is an antagonist with similar afﬁnity for all
muscarinic receptor subtypes [5, 6] which also inhibits
voltage-gated L-type Ca
2?-channels [9–13]. As contrac-
tions of prostate [7] and bladder smooth muscle [8] at least
partly depend on such channels, their inhibition may con-
tribute to the therapeutic effects of propiverine in LUTS
suggestive of benign prostatic hyperplasia and overactive
bladder (OAB), respectively.
Based upon the growing interest in a combination
treatment of male LUTS, we have explored possible a1-
adrenoceptor antagonist effects of propiverine and its
metabolites M-5, M-6, and M-14, which share the anti-
muscarinic and/or L-type Ca
2?-channel-blocking activity
of propiverine [16, 17].
Materials and methods
Prostate and trigone detrusor contraction
Human prostate was obtained with informed written con-
sent in accordance with the regulations of the local hospital
ethical committee (permit EK 194092004) from six patients
undergoing combined prostectomy and radical cystectomy
for invasive bladder cancer (65 ± 3 years). Urinary bladder
trigone from juvenile and adult female pigs were obtained
from a local abattoir. Prostate strips (10 mm long and
3–4 mm wide) and trigone strips (7–10 mm long and
2–4 mm wide without urothelium) were prepared and
mounted in organ baths as previously described [7, 18]
except for a resting load of 5 mN. After an equilibration
period of 60 min, the strips were challenged with a single
concentration of a1-adrenoceptor agonist phenylephrine
(10 lM) to reach a stable pre-contraction after 60 min.
Then, increasing concentrations of test compounds were
added cumulatively (15 min between concentration steps).
Relaxation values were normalized to the 10 lM forskolin
effect, as determined at the end of each experiment, and
were corrected for spontaneous decline of force in time-
matched control (TMC) experiments.
In other experiments, porcine trigone strips were
exposed to cumulatively increasing concentrations of
phenylephrine (30 nM–100 lM) with 5 min of stabiliza-
tion between two subsequent additions. After maximum
contraction was observed, phenylephrine was removed by
washing 3 times with drug-free solution and re-equilibrat-
ing for 60 min. Then a single concentration of test
compound was added and after additional 30 min, a second
concentration-response curve for phenylephrine was
generated.
Radioligand binding
Binding of propiverine and its metabolites to human a1-
adrenoceptor subtypes was analyzed in Chinese hamster
ovary (CHO) cells, expressing approximately 2 pmol
receptor/mg protein, by competition binding against [
3H]-
prazosin as previously described [19, 20]. Phentolamine
was used as a reference antagonist. Radioactivity adherent
to the ﬁlters was quantiﬁed in a Topcount NXT (Perkin
Elmer, Zaventem, Belgium) using Microsint O (Perkin
Elmer) scintillator.
Intracellular Ca
2?
Cells were plated in black, clear bottom 96 wells plates at
50,000 cells per well. After 24 h in serum-free medium,
cells were loaded for 1 h with 4 lM Fluo-4 AM ester in
buffer (HBSS containing 20 mM HEPES and 250 mM
probenecid and 0.42% v/v pluronic acid). They were then
washed twice and incubated for 45 min with buffer.
Fluorescence was measured using an excitation ﬁlter at
485 nm and emission ﬁlter at 520 nm on a NOVOstar
(BMG Labtech, via Isogen, IJselstein, the Netherlands).
After measuring the basal level for 10 s, phenylephrine
(100 pM–10 lM) was added and measured for 50 s, then
5% v/v triton X-100 in basic buffer was added at 10% v/v
to determine the maximal signal (Fmax). After 20 s, 0.1 M
EGTA in buffer was added at 10% v/v to determine the
minimal signal (Fmin). The increase in free intracellular
Ca
2? ([Ca
2?]i) was calculated as the difference between
the [Ca
2?]i for the basal level and after adding a ligand.
[Ca
2?]i was calculated by the equation:
Ca2þ 
i¼ Kd   F   Fmin ðÞ = Fmax   F ðÞ ðÞ
Kd is the dissociation constant of the binding of Fluo-4
to Ca
2? (345 nM). Concentration-response curves for
phenylephrine were generated in duplicate in the absence
and presence of propiverine, its metabolites M-5, M-6, and
M-14 and the reference antagonist phentolamine (added
15 min prior to phenylephrine).
Data analysis
Experimental data were analyzed, by non-linear curve ﬁt-
ting of each individual experiment using GraphPad Prism

4.00 (GraphPad Software, San Diego, CA, USA). Potencies
of propiverine, tamsulosin, and prazosin on phenylephrine
pre-contracted human prostate and porcine trigone strips
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123were determined as -log IC50 [M] values. The potency (-
log EC50 [M]) and efﬁcacy of phenylephrine-induced
contractions and [Ca
2?]i elevations were determined in the
absence and presence of the indicated test compounds.
Maximum contraction during the second concentration-
response curve for phenylephrine (Effmax) was expressed as
percent of the maximum effects during the ﬁrst concen-
tration-response curve (=100%). Inhibitory potency as
determined from competition binding experiments was
transformed to -log Ki values using the Cheng and Prusoff
equation. Statistical differences were tested by Student’s t-
test and were considered signiﬁcant for P\0.05.
Chemicals
[
3H]-prazosin (speciﬁc activity 80 Ci/mmol) was pur-
chased from Perkin Elmer (Zaventem, Belgium). Propi-
verine hydrochloride, M-5 (2,2-diphenyl-2-propoxy-acetic
acid [1-methyl-piperid-4-yl]-ester-N-oxide-trans), M-6
(2,2-diphenyl-2-hydroxy-acetic acid [1-methyl-piperid-4-
yl]-ester-N-oxide-trans), M-14 (2,2-diphenyl-2-propoxy-
acetic acid [piperid-4-yl]-ester), and tamsulosin were syn-
thesized at APOGEPHA Arzneimittel GmbH. Prazosin was
from TOCRIS (Bristol, UK). Fluo-4 AM ester and pluronic
acid were from Molecular Probes (via Invitrogen, Breda,
The Netherlands). Phentolamine, phenylephrine, and all
other chemicals were from SIGMA–ALDRICH (Taufkir-
chen, Germany).
Results
Effects on a1-adrenoceptor-mediated prostate
contraction
At the end of the equilibration period, human prostate strips
exhibited a passive tension of 0.06 ± 0.01 mN/mg wet
weight (n = 16strips/ﬁvepatients).Phenylephrine(10 lM)
increased force of contraction to peak values of 0.16 ± 0.02
mN/mg (n = 19/6), which stabilized at steady-state values
of 0.10 ± 0.02 mN/mg (n = 16/5) within 45 min (Fig. 1a).
The maximum relaxation induced by 10 lM forskolin was
0.07 ± 0.01 mN/mg (n = 16/5). Propiverine, tamsulosin,
and prazosin relaxed phenylephrine-induced contractions in
a concentration-dependent manner (Fig. 1b).
Effects on a1-adrenoceptor-mediated trigone
contraction
Phenylephrine concentration-dependently contracted adult
porcine trigone (but not bladder wall) with maximum con-
tractions of 1.24 ± 0.23 mN/mg wet weight and a -
log EC50 [M] of 5.74 ± 0.04 (n = 6). In juvenile tissues,
these contractions were concentration-dependently reversed
by tamsulosin, prazosin, and propiverine (Fig. 2a). The
overall relaxing effect of propiverine on contractions was
similar in tissue from mature and juvenile animals, but the
potency was lower in mature than in juvenile pigs (-log
IC50 [M] 5.01 ± 0.05 vs. 6.21 ± 0.10, respectively;
n = 5–7; P\0.05; Fig. 2a,b). In trigone from mature pigs
M-14 caused similar relaxation when compared to propi-
verine but with lower potency (4.84 ± 0.08; n = 8;
Fig. 2b). M-5 and M-6 did not inﬂuence trigone contrac-
tions in concentrations up to 100 lM (data not shown).
Concentration-response curves for phenylephrine in
porcine trigone strips in the presence of increasing
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Fig. 1 a Original recordings of force of contraction in a human
prostate tissue strip. The preparation was pre-contracted with
phenylephrine (PE, 10 lM) (left arrow). After stabilization of force,
propiverine or vehicle were added in increasing concentrations
(0.1–100 lM). Finally, forskolin (10 lM) was added for complete
relaxation. The difference between force prior to addition of the test
compound and force in the presence of forskolin was taken as
maximum relaxation (=100%). b Effects of tamsulosin, prazosin, and
propiverine on a1-adrenoceptor-mediated contractions in the human
prostate (calculated –log IC50 values 10.39 ± 0.04, 7.73 ± 0.04, and
4.43 ± 0.08, respectively). Values were corrected for spontaneous
relaxation during time-matched controls, normalized to percent
relaxation by forskolin and expressed as means ± SEM
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123propiverine concentrations demonstrated that inhibition
was largely insurmountable, i.e., mainly consisting of
reduced maximum responses with only minor if any
reductions in apparent potency (Fig. 3).
Binding to a1-adrenoceptor subtypes
Direct a1-adrenoceptor inhibition was evaluated in radioli-
gandbindingassayswithCHOcells.Propiverine,M-14,and
phentolaminecompetedfor[
3H]-prazosinbindingwith-log
Ki values of 4.72 ± 0.01, 4.72 ± 0.04, and 8.62 ± 0.19 at
a1A-,4.94 ± 0.02,5.02 ± 0.11and7.96 ± 0.22ata1B-,and
4.73 ± 0.02, 4.57 ± 0.06 and 7.87 ± 0.04 at a1D-adreno-
ceptors, respectively (Fig. 4). In contrast, the metabolites
M-5 and M-6 had little effect at up to 100 lM.
a1A-Adrenoceptor-mediated intracellular Ca
2?
elevation
The [Ca
2?]i increase with 10 lM phenylephrine was about
1,600 nM, and all subsequent data values are normalized to
that response as measured within a given experiment
(=100%). Propiverine and M-14 concentration-dependently
inhibited the [Ca
2?]i elevations, but this inhibition largely
consisted of reduced maximum responses with small if any
effects on phenylephrine potency (Fig. 5a,b). M-5 or M-6
had little effect (Fig. 5c), whereas antagonism by phen-
tolamine was surmountable (Fig. 5d).
Discussion
Propiverine differs from most other OAB drugs as it is not
only a muscarinic receptor antagonist [5, 6] but also
inhibits L-type Ca
2? channels [9–13]. Based upon the
increasing interest in a combination treatment of male
LUTS [14–16], we have explored possible a1-adrenoceptor
antagonism of propiverine and three of its main metabo-
lites. The a1-adrenoceptor antagonists phentolamine, pra-
zosin, and tamsulosin were used as reference compounds
and exhibited the expected potency for interaction with a1-
adrenoceptors, thereby validating our model systems and
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Fig. 2 a Effects of cumulatively added concentrations of phenyl-
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of the urinary bladder. Data were normalized to mN/mg wet weight of
the detrusor strip. b Effects of increasing concentrations of propiver-
ine in comparison to those of the a1-adrenoceptor antagonists
tamsulosin and prazosin on juvenile porcine detrusor strips from the
trigone area of the urinary bladder. Strips were pre-contracted with
10 lM of the a1-adrenoceptor agonist phenylephrine. c Effects of
increasing concentrations of propiverine and its metabolites M-5 and
M-6 and d effects of propiverine and M-14 on trigone detrusor strips
from mature pigs pre-contracted with phenylephrine (10 lM). Data in
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123techniques. Due to limited access to human prostate
specimen for organ bath experiments as well as smaller
signal/noise ratios, we have used porcine trigone as a well
established animal model of a1-adrenoceptor-mediated
contraction of urological tissue for more detailed analysis.
Our data demonstrate concentration-dependent relaxa-
tion of phenylephrine-induced tone of human prostate and
porcine trigone. At least in trigone, similar relaxation was
observed with the propiverine metabolite M-14 but not
with M-5 or M-6. As phenylephrine-induced contraction in
these two preparations is a1-adrenoceptor-mediated [17],
this relaxation provided initial evidence for a1-adrenocep-
tor antagonism by propiverine and M-14. However, L-type
Ca
2? channels contribute to prostate and bladder contrac-
tion [9, 10]. The direct interaction of propiverine and its
metabolites with a1-adrenoceptors was demonstrated in
competition binding studies with cloned human a1-adre-
noceptor subtypes, yielding afﬁnities in line with their
potency to relax human prostate and porcine trigone. To
verify that the inhibition of radioligand binding was indeed
associated with receptor antagonism, concentration-
dependent inhibition of phenylephrine-induced [Ca
2?]i
elevation was demonstrated. In contrast to tissue relaxation
experiments, inhibition of [Ca
2?]i elevation in CHO cells
cannot be explained by Ca
2? channel-blocking properties
of propiverine, because CHO cells do not express such
L-type Ca
2? channels. Together these experiments dem-
onstrate that propiverine and its metabolite M-14 bind to
and inhibit human a1-adrenoceptors and accordingly can
relax a1-adrenoceptor-mediated contraction of human
prostate and porcine trigone.
Propiverine is a competitive antagonist with similar
afﬁnity for all muscarinic receptor subtypes [5, 6, 11].
However, the antagonism of [Ca
2?]i elevations in CHO
cells and of contraction in porcine trigone was
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123insurmountable. Thus, the molecular interaction of propi-
verine with a1-adrenoceptors and muscarinic receptors
occurs in a different way despite the drug being an
antagonist for both receptor families. This differential
interaction is also supported by the fact that the propiverine
metabolites M-5 and M-6 lacked a1-adrenoceptor effects
but inhibit muscarinic receptor function [5, 10, 18, 19].
The afﬁnity of propiverine for a1-adrenoceptors in the
present study differs from that for human M3 receptors by
50- to 100-fold [5, 6, 12] but is very similar to its potency
for inhibition of L-type Ca
2? channels [12]. As muscarinic
antagonists typically are dosed to yield high receptor
occupancy rates [20], it can be expected that therapeutic
doses of propiverine exhibit some degree of a1-adreno-
ceptor antagonism and L-type Ca
2? channel blockade.
Based upon reported plasma concentrations of propiverine
(parent compound alone) [21] and our afﬁnity estimates
from the radioligand binding studies, therapeutic propi-
verine concentrations could occupy up to 10% of a1-
adrenoceptors. While this may be less pronounced than the
blockade of muscarinic receptors, it may nevertheless
contribute to the clinical proﬁle of propiverine and spe-
ciﬁcally may be beneﬁcial for the treatment of male LUTS.
Moreover, the insurmountable antagonism at a1- (but not
muscarinic) receptors raises the possibility that even lim-
ited a1-adrenoceptor occupancy will yield considerable
inhibition over time. Interestingly, a large recent observa-
tional study reported that the clinical effects of propiverine
against OAB symptoms were quantitatively similar in men
when administered alone or as add-on to an existing a-
blocker treatment [22]. While these ﬁndings do not prove
a1-antagonism of propiverine in vivo, they are in line with
this proposal. However, dedicated studies will be required
to determine the clinical relevance of such effects. They
should also take into account that propiverine and its var-
ious metabolites differ in their in vivo plasma concentra-
tions [23]. For each of them, the relative contribution of the
three molecular targets may differ in the generation of
bladder selectivity and the overall relaxing effect in the
lower urinary tract [24]. Even if propiverine itself turns out
to have too little a1-antagonism in vivo, it is an exciting
starting point for the future synthesis of balanced a1/mus-
carinic receptor antagonists.
Conclusions
In contrast to other drugs used for the treatment of OAB,
propiverine is not only a muscarinic receptor antagonist but
also has L-type Ca
2? channel blocking and a1-adrenocep-
tor antagonist effects. While each of these effects may be
beneﬁcial in the treatment of voiding dysfunction, includ-
ing male LUTS, the relative contribution of these mecha-
nisms and of the propiverine metabolites to the overall
therapeutic effects upon oral administration of propiverine
remains to be determined.
Acknowledgments This study was funded and supported in part by
the Bundesministerium fu ¨r Wirtschaft, Germany (PRO INNO II,
KA0558501UL7), Coordination Theme 1 (Health) of the European
Community’s FP7, Grant agreement number HEALTH-F2-2008-
223234, and by APOGEPHA Arzneimittel GmbH, Dresden, Ger-
many. MB and GJS are employees of Apogepha. MC Michel has
received research support, lecturer and/or consultant honoraria in the
anti-muscarinic ﬁeld from Allergan, Astellas, Bayer, Boehringer In-
gelheim, Pﬁzer, Schwarz Pharma, Theravance.
150 DMSO 1% (4)
i
n
e
)
150 DMSO 1% (4
n
e
) B A
100
150
+ 100 μM M-14 (4)
+ 30 μM M-14 (4)
%
 
P
h
e
n
y
l
e
p
h
r
i
100
150
+ 100 μM  propiverine (5)
+ 30 μM  propiverine (5)
+ 10 μM propiverine (5)
(  )
%
 
P
h
e
n
y
l
e
p
h
r
i
-10 -9 -8 -7 -6 -5 C
- 1 0 - 9- 8- 7- 6- 5 C
0
50
[
C
a
2
+
]
i
 
,
(
%
-10 -9 -8 -7 -6 -5 C
-10 -9 -8 -7 -6 -5 C
0
50
[
C
a
2
+
]
i
 
,
(
%
log [Phenylephrine] (M)
150 DMSO 1% (4)
n
e
)
log [Phenylephrine] (M)
150 DMSO 1% (4)
n
e
) D C
100
150
+ 100 μM M-6 (4)
+ 100 μM M-5 (4)
 
P
h
e
n
y
l
e
p
h
r
i
n
100
150
+ 20 nM phentolamine (4)
+ 100 nM phentolamine (4)
+ 200 nM phentolamine (4)
 
P
h
e
n
y
l
e
p
h
r
i
n
0
50
[
C
a
2
+
]
i
 
,
(
%
0
50
[
C
a
2
+
]
i
 
,
(
%
log [Phenylephrine] (M) log [Phenylephrine] (M)
Fig. 5 Phenylephrine-
stimulated elevation of [Ca
2?]i
in a1A-adrenoceptor-expressing
CHO cells. a Control
concentration-response curves
in the presence of DMSO, and
responses to increasing
concentrations of propiverine.
The vehicle DMSO did not
signiﬁcantly affect the efﬁcacy
or potency of phenylephrine to
raise [Ca
2?]i (n = 4), data not
shown. b Responses to M-14
and c responses to M-5 and
M-6. d Responses to
phentolamine. Data were
normalized to [Ca
2?]i increase
in the presence of 10 lM
phenylephrine (=100%).
Means ± SEM from 4–5
experiments
154 World J Urol (2011) 29:149–155
123Conﬂict of interest The other authors do not report a conﬂict of
interest other than those listed under Acknowledgments.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Saito H, Yamada T, Oshima H et al (1999) A comparative study
of the efﬁcacy and safety of tamsulosin hydrochloride (Harnal
capsules) alone and in combination with propiverine hydrochlo-
ride (BUP-4 tablets) in patients with prostatic hypertrophy asso-
ciated with pollakiuria and/or urinary incontinence. Jpn J Urol
Surg 12:525–536
2. Lee K-S, Choo M-S, Kim D-Y et al (2005) Combination treat-
ment with propiverine hydrochloride plus doxazosin controlled
release gastrointestinal therapeutic system formulation for over-
active bladder and coexisting benign prostatic obstruction: a
prospective, randomized, controlled multicenter study. J Urol
174:1334–1338
3. Maruyama O, Kawachi Y, Hanazawa K et al (2006) Naftopidil
monotherapy vs naftopidil and an anticholinergic agent combined
therapy for storage symptoms associated with benign prostatic
hyperplasia: a prospective randomized controlled study. Int J
Urol 13:1280–1285
4. Yokoyama T, Uematsu K, Watanabe T et al (2009) Naftopidil
and propiverine hydrochloride for treatment of male lower uri-
nary tract symptoms suggestive of benign prostatic hyperplasia
and concomitant overactive bladder: a prospective randomized
controlled study. Scand J Urol Nephrol 43:307–314
5. Wuest M, Weiss A, Waelbrock M et al (2006) Propiverine and
metabolites: differences in binding to muscarinic receptors and in
functional models of detrusor contraction. Naunyn-Schmiede-
berg’s Arch Pharmacol 374:87–97
6. Maruyama S, Oki T, Otsuka A et al (2006) Human muscarinic
receptor binding characteristics of antimuscarinic agents to treat
overactive bladder. J Urol 175:365–369
7. Chueh S-C, Guh J-H, Chen J et al (1996) Inhibition by tamsulosin
of tension responses of human hyperplastic prostate to electrical
ﬁeld stimulation. Eur J Pharmacol 305:177–180
8. Frazier EP, Peters SLM, Braverman AS et al (2008) Signal
transduction underlying control of urinary bladder smooth muscle
tone by muscarinic receptors and b-adrenoceptors. Naunyn-
Schmiedeberg’s Arch Pharmacol 377:449–462
9. Christ T, Wettwer E, Wuest M et al (2008) Electrophysiological
proﬁle of propiverine—relationship to cardiac risk. Naunyn-
Schmiedeberg’s Arch Pharmacol 376:431–440
10. Wuest M, Hecht J, Christ T et al (2005) Pharmacodynamics of
propiverine and three of its metabolites on detrusor contraction.
Br J Pharmacol 145:608–619
11. Tokuno H, Chowdhury JU, Tomita T (1993) Inhibitory effects of
propiverine on rat and guinea-pig urinary bladder muscle. Nau-
nyn-Schmiedeberg’s Arch Pharmacol 348:659–662
12. Uchida S, Kurosawa S, Fujino T et al (2007) Binding activities by
propiverine and its N-oxide metabolites of L-type calcium
channel antagonist receptors in the rat bladder and brain. Life Sci
80:2454–2460
13. Zhu H-L, Brain KL, Aishima M et al (2008) Actions of two main
metabolites of propiverine (M-1 and M-2) on voltage-dependent
L-type Ca
2? currents and Ca
2? transients in murine urinary
bladder myocytes. J Pharmacol Exp Ther 324:118–127
14. Lee K-S, Lee HW, Han DH (2008) Does anticholinergic medi-
cation have a role in treating men with overactive bladder and
benign prostatic hyperplasia? Naunyn-Schmiedeberg’s Arch
Pharmacol 377:491–501
15. Andersson K-E (2007) LUTS treatment: future treatment options.
Neurourol Urodyn 26:934–947
16. Athanasopoulos A, Perimenis P (2005) Efﬁcacy of the combi-
nation of an a1-blocker with an anticholinergic agent in the
treatment of lower urinary symptoms associated with bladder
outlet obstruction. Exp Opin Pharmacother 6:2429–2433
17. Michel MC, Vrydag W (2006) a1-, a2- and b-adrenoceptors in the
urinary bladder, urethra and prostate. Br J Pharmacol 147:S88–
S119
18. Wuest M, Braeter M, Schoeberl C et al (2005) Juvenile pig
detrusor: effects of propiverine and three of its metabolites. Eur J
Pharmacol 524:145–148
19. Propping S, Braeter M, Grimm M-O et al (2010) Anticholinergic
effects of cis- and trans-isomers of two metabolites of propi-
verine. Naunyn-Schmiedeberg’s Arch Pharmacol 381:329–338
20. Hegde SS (2006) Muscarinic receptors in the bladder: from basic
research to therapeutics. Br J Pharmacol 147:S80–S87
21. Guay DRP (2003) Clinical pharmacokinetics of drugs used to
treat urge incontinence. Clin Pharmacokin 42:1243–1285
22. Oelke M, Murgas S, Baumann I et al (2011) Efﬁcacy of propi-
verine ER with or without a-blockers related to maximum urinary
ﬂow rate in adult men with OAB: results of a 12-week, multi-
center, non-interventional study. World J Urol. doi:10.1007/
s00345-011-0654-7
23. May K, Westphal K, Giessmann T et al (2008) Disposition and
antimuscarinic effects of the urinary bladder spasmolytics pro-
piverine: inﬂuence of dosage forms and circadian-time rhtyhms.
J Clin Pharmacol 48:570–579
24. Yamada S, Ito Y, Taki Y et al (2010) The N-oxide metabolite
contributes to bladder selectivity resulting from oral propiverine:
muscarinic receptor binding and pharmacokinetics. Drug Metab
Dispos 38:1314–1321
World J Urol (2011) 29:149–155 155
123